Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

short stature, Brussels type - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

short stature, Brussels type

MONDO:0011046

Also known as:Mievis-Verellen-Dumoulin syndromefamilial short stature with facial dysmorphism and osteochondrodysplastic lesionsshort stature syndrome, Brussels type

Overview

This syndrome is characterized by short stature presenting in the neonatal period associated with osteochondrodysplastic lesions and facial dysmorphism.

Treatments10 FDA approved

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include very common findings: Growth delay, Abnormal facial shape, and Short stature; and common findings: Horseshoe kidney, Macrocephaly, Microretrognathia, and Triangular face and others.

Organ System	Phenotype Count	Example Features
Head and neck	3	Abnormal facial shape, Macrocephaly, Triangular face

Diagnosis

Biomarker and diagnostic research for short stature, Brussels type has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for short stature, Brussels type, including somatropin (Nutropin, approved 1993). An additional 1 compound holds orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Phenotype severity distribution: 3 very common features, 7 common features.

Estimated prevalence: <1 in 1,000,000 (VERY_RARE).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for short stature, Brussels type.

162 publications have been identified in PubMed for short stature, Brussels type. Research spans Review / Meta-Analysis (52%), Basic Science / Preclinical (16%), and Epidemiology / Natural History (12%).

Research Type	Count	% of Total
Research summaries	84	52%

Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 7:49 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:601350

Orphanet

European rare disease database

Orphanet:2867

GARD

Genetic and Rare Diseases Info Center

GARD:4838

Questions for Your Care Team

→What are the benefits and potential side effects of Nutropin for managing short stature, Brussels type?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Kisho

short stature, Brussels type

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications

short stature, Brussels type

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications